Acrivon Therapeutics, Inc. ( (ACRV) ) just unveiled an update.
On April 7, 2025, Acrivon Therapeutics announced the appointment of Mansoor Raza Mirza, M.D., as Chief Medical Officer, effective April 9, 2025. Dr. Mirza, a distinguished oncologist with a robust background in gynecologic oncology, will lead clinical development efforts, including the ongoing ACR-368 Phase 2b trial in endometrial cancer and the ACR-2316 Phase 1 study. His appointment is expected to strengthen Acrivon’s clinical leadership and advance the company’s pipeline towards regulatory submissions and potential approvals, enhancing its position in the precision oncology field.
Spark’s Take on ACRV Stock
According to Spark, TipRanks’ AI Analyst, ACRV is a Underperform.
Acrivon’s overall stock score is low due to significant financial challenges, including no revenue, increasing losses, and negative cash flows. The weak technical indicators further compound these concerns. However, recent corporate events showing progress in clinical programs and an extended cash runway offer some optimism for future prospects.
To see Spark’s full report on ACRV stock, click here.
More about Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing precision oncology medicines. Utilizing its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, the company aims to design and develop drug candidates that match mechanistically with patients whose tumors are predicted to be sensitive to specific treatments. Acrivon is advancing its lead candidate, ACR-368, for endometrial cancer and is also developing ACR-2316, a novel WEE1/PKMYT1 inhibitor.
YTD Price Performance: -73.46%
Average Trading Volume: 117,256
Technical Sentiment Signal: Strong Buy
Current Market Cap: $47.34M
See more insights into ACRV stock on TipRanks’ Stock Analysis page.